News

“Notice of Convocation of the 157th Annual General Meeting of Shareholders” and “Items Disclosed on Internet Concerning Notice of Convocation of the 157th Annual General Meeting of Shareholders”

Shionogi Announces appointment of Corporate officers, Corporate Reorganization and Personnel Reassignment

Transcript of Fiscal 2021 Financial Results Conference Call

Shionogi & Co., Ltd. and F2G Ltd., Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia

Notice Regarding the Initiation of a Phase 2/3 clinical trial in Japanese adolescents for the COVID-19 Recombinant Protein-based Vaccine, S-268019

Presentation Material for Conference Call of FY2021

Notice Regarding Establishment of the “Shionogi Infectious Disease Research Promotion Foundation”, a General Incorporated Foundation, and Disposition, Acquisition and Cancellation of Treasury Stock

Financial Results, Supplement, and Press conference Material for FY2021

Position and Policy Regarding Reduction of the Investment Unit

Notice of Revisions to Earnings and Dividend Forecasts

New Data for Shionogi’s COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance

Shionogi Presents Japanese Phase 2/3 Clinical Trial Results of COVID-19 Recombinant Protein-based Vaccine at Conference

Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine

Notice Regarding the Media Coverage about S-217622, a Therapeutic Drug for COVID-19

Shionogi expresses its support for the recommendations of Task Force on Climate-related Financial Disclosures (TCFD) and its participation in the TCFD Consortium

Shionogi has been Selected for the ESG Investment Index “FTSE Blossom Japan Sector Relative Index” Adopted by GPIF

AMR Action Fund Launches Investments to Promote Innovation to Overcome AMR

Continuation of the Cooperation Agreement with Aichi Prefecture on Drug Abuse Prevention

Notice Regarding Completion of Reorganization of Subsidiary through Company Merger

SMBC Nikko Web IR for Retail Investors

Notice Regarding the Signing of a Basic Agreement with the Ministry of Health, Labor and Welfare for Domestic Supply of S-217622, a Therapeutic Drug for COVID-19

Regarding the Filing for Approval of Cefiderocol in Japan

ACTG and Shionogi Announce Progress on Global Phase 3 Trial of Novel COVID-19 Oral Antiviral Agent S-217622

Shionogi Announces the Results of Comprehensive Maternal and Child Health Support Activities undertaken in Kenya under the “Mother to Mother SHIONOGI Project” —Health of Maasai Mothers and Children has Improved—

Shionogi provides humanitarian aid to Ukraine

Shionogi Presents the Interim Report (Top-line Results) of a Phase 2/3 Additional Dose Clinical Trial for the COVID-19 Vaccine, S-268019

Presentation Material for Briefing session on Phase 2/3 booster trial of COVID-19 vaccine "S-268019"

Shionogi Received a “Special Award” in the Category of Corporate Environmental Sustainability of the Ministry of the Environment’s 3rd ESG Finance Awards Japan

Shionogi and Ube Industries Enter into a Strategic Development Collaboration for the Novel Anti-RS Virus Drug Candidate S-337395

Conclusion of a Business Cooperation Agreement regarding Support for Children’s Bright Future with the City of Yokohama

Shionogi Files for Approval of S-217622, a Therapeutic Drug for COVID-19, in Japan

SHIONOGI Announces Sponsorship of the Thematic Projects "Signature Pavilion" of Expo 2025 Osaka, Kansai, Japan

Shionogi has been recognized as one of the highest-ranking companies on the “Supplier Engagement Reporting Leaderboard (Climate Change)” by CDP

Shionogi has been Selected as one of the "Excellent Integrated Reports" by the GPIF's Domestic Equity Managers for the second consecutive year

Shionogi Announces the Conclusion of a Contract for the Establishment of a Research Department for Mucosal Vaccines with Chiba University Hospital.

Transcript of Briefing session on COVID-19 therapeutic drug "S-217622

SHIMADZU and SHIONOGI establishes joint venture AdvanSentinel —Helping society through better public health risk assessment, including wastewater surveillance—

Presentation Material for Briefing session on COVID-19 therapeutic drug "S-217622"

Shionogi Presents Phase 2/3 Clinical Trial Results (Phase 2a Part) for the COVID-19 Therapeutic Drug S-217622

Transcript of 3rd Quarter of Fiscal 2021 Financial Results Conference Call

Shionogi Presents Clinical Trial Results of the COVID-19 Therapeutic Drug S-217622

Presentation Material for FY2021 Third Quarter Financial Results

Financial Results for the Third Quarter of FY2021

Notice Regarding the Progress of S-217622 to Fight COVID-19

Notice Regarding the Initiation of an Active Control Neutralizing Antibody Comparative Clinical Trial for COVID-19 Recombinant Protein-based Vaccine, S-268019 in Japan

Shionogi Announces Commitment to Fight COVID-19